Drexel University

Alliance Discovery, Inc.

Philadelphia Health and Education Corporation

Imclone LLC

Alessandro Fatatis

Joseph M Salvino

Olimpia Meucci

Fei Shen

Whitney L Gladney

Xin Feng

Nick Loizos

Jim Huber

Whitney L Jamieson

Danielle Jernigan

Nathan Graeme Dolloff

Kristina Susan Shahriari

The disclosure provides compounds of formula (II) having the structure: Compounds of formula (II) are fractalkine receptor agonists and useful in treating, preventing or minimizing metastasis in a subject diagnosed with cancer. The compounds of the disclosure are further useful in treating central nervous system diseases (such as, but not limited to, HIV Associated Neurocognitive Disorders (HAND), and/or Alzheimer's disease), pain, inflammation (such as, but not limited to, arthritis), cardiovascular disease (such as, but not limited to, undesired vascular smooth muscle proliferation, atherosclerosis, coronary vascular endothelial dysfunction, and/or coronary artery disease), and/or multiple sclerosis.

Substituted pyrrolo[1,2-α]quinoxalin-4(5H)-ones as CXCR1 antagonists

The disclosure provides compounds of formula (I) having the structure:  Compounds of formula (I) are fractalkine receptor agonists and useful in treating, preventing or minimizing metastasis in a subject diagnosed with cancer. The compounds of the invention are further useful in treating central nervous system diseases (such as, but not limited to, HIV Associated Neurocognitive Disorders (HAND), and/or Alzheimer's disease), pain, inflammation (such as, but not limited to, arthritis), cardiovascular disease (such as, but not limited to, undesired vascular smooth muscle proliferation, atherosclerosis, coronary vascular endothelial dysfunction, and/or coronary artery disease), and/or multiple sclerosis.

Substituted pyrrolo[1,2-a]quinoxalin-4(5H)-ones as CX3CR1 antagonists

The invention includes a method of preventing or treating metastasis in a subject diagnosed with prostate cancer. In certain embodiments, the metastasis comprises bone cancer. In other embodiments, the subject suffers from castration-resistant prostate cancer.

Method of treating androgen receptor negative prostate tumors and their metastases

The present invention includes compositions that are useful in preventing or treating metastasis in a subject diagnosed with cancer. The present invention also includes methods of preventing or treating metastasis in a subject diagnosed with cancer, wherein the method comprises administering to the subject in need thereof an effective amount of a pharmaceutical formulation comprising at least one pharmaceutically acceptable carrier and at least one CXCR1 or fractalkine antagonist.

Compounds useful for inhibiting metastasis from cancer and methods using same

Methods of inhibiting metastasis from cancer

The invention provides methods of treating bone cancer, particularly metastatic bone cancer, by administering a PDGFR alpha antagonist. The invention further provides methods of treating a mammal with a neoplastic disease using the antibodies alone or in combination with other agents.

Methods of treating secondary bone tumors with antibodies against PDGFR alpha

Growing community of inventors

Penn Valley, PA, United States of America

Alessandro Fatatis